Delivery Order SPE2DR25D2002-SPE2DR26FBRU7
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $14,183.70 to supply 200-unit vials of Xeomin, a botulinum toxin product used for medical purposes. The contract is a firm fixed-price delivery order with an ultimate completion date of November 21, 2025, and was awarded on October 30, 2025, through a non-set-aside competitive procurement. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,174.80 for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This non-set-aside, competitively awarded contract employs firm fixed pricing and is scheduled for completion by November 17, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $49,461.72 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications. This firm fixed-price contract, awarded November 5, 2025, with completion targeted for November 28, 2025, represents a competitively awarded procurement with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,352.44 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin injection used for medical and therapeutic purposes. The contract, awarded on November 6, 2025, with an ultimate completion date of December 1, 2025, represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $1,396.85 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed price delivery order, issued on July 24, 2025, with an ultimate completion date of August 14, 2025, will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This...
- The Defense Logistics Agency awarded a delivery order valued at $23,553.20 to AmerisourceBergen Drug Corp for the supply of 200-unit vials of Xeomin, a botulinum toxin-based pharmaceutical product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on November 3, 2025, with an ultimate completion date of November 25, 2025, represents a non-competitive award without set-aside designation. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $11,174.80 firm fixed price delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications. This non-set-aside competitive award was issued on September 5, 2025, with an ultimate completion date of September 26, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as...
- The Defense Logistics Agency awarded a $55,874 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This firm fixed-price, competitively awarded contract is scheduled for completion by October 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract includes no set-aside designation, indicating it was awarded through open competition. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,676.22 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on March 18, 2025, is scheduled for completion by April 8, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award was competitively procured with no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,766.46 and is scheduled for completion by November 26, 2025. The award was issued on November 4, 2025, with no set-aside designation applied. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a...
- SPE2DR25D2002Indefinite Delivery Contract
- SPE2DR25D2002-SPE2DR26FBRU7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,472.05 to AmerisourceBergen Drug Corp for 100 unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications. This competitive, non-set-aside contract was awarded on November 10, 2025, with an ultimate completion date of December 3, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The firm fixed price delivery order represents a routine pharmaceutical procurement under the Defense Logistics Agency's medical supply chain operations. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of medications, vaccines, medical devices, and specialized healthcare commodities to support military and veteran healthcare systems. The parent IDC serves as a flexible contracting vehicle enabling the company to fulfill diverse pharmaceutical needs across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems on a global basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 11/10/25 |